Resistência ao tratamento nos transtornos de ansiedade: fobia social, transtorno de ansiedade generalizada e transtorno do pânico

OBJETIVOS: Os transtornos de ansiedade são condições psiquiátricas prevalentes que determinam importante prejuízo funcional, piora na qualidade de vida do indivíduo e um enorme custo social. Embora diversas medicações eficazes para os transtornos de ansiedade encontrem-se disponíveis, um número sign...

Full description

Saved in:
Bibliographic Details
Published inRevista brasileira de psiquiatria Vol. 29; no. suppl 2; pp. S55 - S60
Main Authors Menezes, Gabriela Bezerra de, Fontenelle, Leonardo F, Mululo, Sara, Versiani, Márcio
Format Journal Article
LanguageEnglish
Published 01.10.2007
Online AccessGet full text

Cover

Loading…
Abstract OBJETIVOS: Os transtornos de ansiedade são condições psiquiátricas prevalentes que determinam importante prejuízo funcional, piora na qualidade de vida do indivíduo e um enorme custo social. Embora diversas medicações eficazes para os transtornos de ansiedade encontrem-se disponíveis, um número significativo de pacientes não responde adequadamente ao tratamento e muitos permanecem com sintomas residuais clinicamente significativos. O objetivo deste estudo é rever aspectos relacionados à resistência ao tratamento e estratégias farmacológicas no manejo dos transtornos de ansiedade resistentes ao tratamento. MÉTODO: Revisão narrativa. RESULTADOS: São discutidos os diversos aspectos conceituais relacionados à resistência ao tratamento, os possíveis preditores de resistência e, finalmente, algumas estratégias a serem utilizadas no manejo dos transtornos de ansiedade (incluindo transtorno de ansiedade social, transtorno de ansiedade generalizada e transtorno do pânico) que não respondem às abordagens terapêuticas convencionais. CONCLUSÃO: A resistência ao tratamento ainda é um desafio para a prática clínica que começa em conceitos não operacionalizados de resposta e resistência e termina na escassez de estudos controlados sobre estratégias de tratamento nesse último cenário clínico. OBJECTIVES: Anxiety disorders are common psychiatric conditions that cause significant disability, poor quality of life and enormous social cost. Although treatments with demonstrable efficacy are available a great number of patients fail to respond or remains with clinically significant residual symptoms after treatment. The objective of this study is to review aspects related to treatment resistance and pharmacological strategies to deal with anxiety disorders resistant to treatment. METHOD: Narrative review. RESULTS: We discuss conceptual aspects related to treatment resistance or refractoriness, predictors of poor treatment outcome, and finally, some strategies to deal with anxiety disorders (including social anxiety disorder, generalized anxiety disorder and panic disorder) that do not respond to standard therapeutic interventions. CONCLUSION: Treatment resistance in anxiety disorders remains a challenge to clinical practice going from non standardized concepts of response and resistance to a paucity of controlled studies concerning therapeutic strategies.
AbstractList OBJETIVOS: Os transtornos de ansiedade são condições psiquiátricas prevalentes que determinam importante prejuízo funcional, piora na qualidade de vida do indivíduo e um enorme custo social. Embora diversas medicações eficazes para os transtornos de ansiedade encontrem-se disponíveis, um número significativo de pacientes não responde adequadamente ao tratamento e muitos permanecem com sintomas residuais clinicamente significativos. O objetivo deste estudo é rever aspectos relacionados à resistência ao tratamento e estratégias farmacológicas no manejo dos transtornos de ansiedade resistentes ao tratamento. MÉTODO: Revisão narrativa. RESULTADOS: São discutidos os diversos aspectos conceituais relacionados à resistência ao tratamento, os possíveis preditores de resistência e, finalmente, algumas estratégias a serem utilizadas no manejo dos transtornos de ansiedade (incluindo transtorno de ansiedade social, transtorno de ansiedade generalizada e transtorno do pânico) que não respondem às abordagens terapêuticas convencionais. CONCLUSÃO: A resistência ao tratamento ainda é um desafio para a prática clínica que começa em conceitos não operacionalizados de resposta e resistência e termina na escassez de estudos controlados sobre estratégias de tratamento nesse último cenário clínico. OBJECTIVES: Anxiety disorders are common psychiatric conditions that cause significant disability, poor quality of life and enormous social cost. Although treatments with demonstrable efficacy are available a great number of patients fail to respond or remains with clinically significant residual symptoms after treatment. The objective of this study is to review aspects related to treatment resistance and pharmacological strategies to deal with anxiety disorders resistant to treatment. METHOD: Narrative review. RESULTS: We discuss conceptual aspects related to treatment resistance or refractoriness, predictors of poor treatment outcome, and finally, some strategies to deal with anxiety disorders (including social anxiety disorder, generalized anxiety disorder and panic disorder) that do not respond to standard therapeutic interventions. CONCLUSION: Treatment resistance in anxiety disorders remains a challenge to clinical practice going from non standardized concepts of response and resistance to a paucity of controlled studies concerning therapeutic strategies.
Author Fontenelle, Leonardo F
Menezes, Gabriela Bezerra de
Versiani, Márcio
Mululo, Sara
Author_xml – sequence: 1
  givenname: Gabriela Bezerra de
  surname: Menezes
  fullname: Menezes, Gabriela Bezerra de
  organization: Universidade Federal do Rio de Janeiro, Brasil
– sequence: 2
  givenname: Leonardo F
  surname: Fontenelle
  fullname: Fontenelle, Leonardo F
  organization: Universidade Federal do Rio de Janeiro, Brasil
– sequence: 3
  givenname: Sara
  surname: Mululo
  fullname: Mululo, Sara
  organization: Universidade Federal do Rio de Janeiro, Brasil
– sequence: 4
  givenname: Márcio
  surname: Versiani
  fullname: Versiani, Márcio
  organization: Universidade Federal do Rio de Janeiro, Brasil
BookMark eNqdjzFuwkAQRVcRkYDAGdgDBDILxg5pERE1pF8N9jhaZHbQzjakzU0ouQYXw44iBEqXYjT_679f_K5qefak1MDAyExn8LI2U5MOkyRJxwAZAKT1QfKgOtegdaPbqiuyBRhnk9eso75XJE7i-eRzhxpZx4ARd-Qja8_SWC-RQ6ML0rVxVGBBb7rkTd0QrnvV8w13h-lP8hSwcl9YoKY7jPX-fPQu5556LLES6v_-J5W9Lz7my2EeWCRQaffB7TAcrAHbbLY_m-2fzZP_Ny_RBGXs
Cites_doi 10.4088/JCP.v67n0307
10.4088/JCP.v66n1016
10.1097/01.jcp.0000177853.15910.de
10.4088/JCP.v63n0113
10.1001/archpsyc.1994.03950010008002
10.4088/JCP.v67n0914
10.1176/appi.ajp.157.4.659-a
10.1056/NEJMsa043266
10.1097/00004714-200302000-00015
10.1097/00004850-199907000-00006
10.1097/00004714-199602000-00014
10.4088/JCP.v62n0813d
10.1186/1745-0179-2-35
10.1002/da.10086
10.1192/bjp.bp.105.012799
10.1016/S0006-3223(97)00390-9
10.1080/08039480310002110
10.4088/PCC.v02n0301
10.1097/00004850-200501000-00002
10.1002/da.20050
10.3109/15622970009150563
10.1002/da.10096
10.4088/JCP.v65n1213
10.1016/0165-0327(96)00030-4
10.1097/00004850-200015060-00004
10.1097/01.jcp.0000248620.34541.bc
10.1176/appi.ajp.163.3.548
10.1176/appi.ajp.158.10.1725
10.1192/bjp.173.1.54
10.1097/01.jcp.0000195108.01898.17
10.1007/s00213-004-1957-9
10.1097/00004714-200010000-00011
10.1176/appi.ajp.160.4.749
10.1016/S0193-953X(05)70254-9
10.1002/hup.421
10.4088/JCP.v68n0221e
10.1176/ajp.155.7.992
10.1097/01.jcp.0000155821.74832.f9
10.1016/j.jad.2005.05.003
10.1017/S1092852900022148
10.1017/S1092852900022392
10.1177/026988110201600412
10.1055/s-2004-832600
10.1016/j.biopsych.2005.07.005
10.1590/S1516-44462006000400003
10.1097/01.jcp.0000084025.22282.84
10.1177/070674379804300109
10.1038/sj.mp.4001852
10.1097/00005053-198608000-00006
10.1017/S1092852900022355
ContentType Journal Article
DBID AAYXX
CITATION
DOI 10.1590/S1516-44462007000600004
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Psychology
EISSN 1516-4446
EndPage S60
ExternalDocumentID 10_1590_S1516_44462007000600004
GroupedDBID 0R~
0SF
123
29P
2WC
457
5VS
6I.
AACTN
AAEDT
AAEDW
AAFTH
AAIKJ
AALRI
AAXUO
AAYXX
ABDBF
ABDHV
ABIVO
ABMAC
ABXHO
ACGFO
ACGFS
ACHQT
ADBBV
ADEZE
ADVLN
AEGXH
AENEX
AEXQZ
AGHFR
AIAGR
AITUG
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APOWU
AZFZN
B14
BAWUL
BCNDV
CITATION
CS3
DIK
DU5
E3Z
EBD
EBS
EFA
EJD
ESX
FAEIB
FDB
GROUPED_DOAJ
GX1
HYE
HZ~
IPNFZ
IXB
KQ8
M~E
NCXOZ
O-L
O9-
OK1
P2P
PGMZT
RIG
RNS
RPM
RSC
SCD
SSZ
TR2
XSB
~8M
ID FETCH-crossref_primary_10_1590_S1516_444620070006000043
ISSN 1516-4446
IngestDate Fri Aug 23 03:09:14 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue suppl 2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-crossref_primary_10_1590_S1516_444620070006000043
ParticipantIDs crossref_primary_10_1590_S1516_44462007000600004
PublicationCentury 2000
PublicationDate 2007-10-00
PublicationDateYYYYMMDD 2007-10-01
PublicationDate_xml – month: 10
  year: 2007
  text: 2007-10-00
PublicationDecade 2000
PublicationTitle Revista brasileira de psiquiatria
PublicationYear 2007
References Sepede G (ref19) 2006; 26
Cournoyer J (ref59) 1986; 31
Snyderman SH (ref16) 2005; 25
Katerndahl DA (ref22) 2003; 17
Simon NM (ref17) 2006; 67
Menza MA (ref52) 2001; 27
Etxebeste M (ref65) 2000; 157
Kinrys G (ref50) 2003; 18
Zwanzger P (ref61) 2001; 62
Worthington JJ 3rd (ref32) 2005; 20
Pallanti S (ref38) 2006; 2
Simon NM (ref46) 2002; 7
Van Ameringen M (ref23) 2004; 9
Pallanti S (ref14) 2006; 2
Pollack MH (ref21) 2003; 23
Pollack MH (ref15) 1998; 155
Hollifield M (ref39) 2005; 21
Hirschmann S (ref13) 2000; 20
Buch S (ref41) 2007; 68
Kessler RC (ref3) 1994; 51
Mitte K (ref9) 2005; 88
Van Ameringen M (ref45) 1996; 39
Schwartz TL (ref40) 2002; 36
Aarre TF (ref42) 2003; 57
Wittchen HU (ref6) 2001; 24
Liebowitz MR (ref27) 2002; 63
Ontiveros A (ref57) 1992; 17
Stein MB (ref26) 2005; 177
Altamura AC (ref47) 1999; 14
Versiani M (ref44) 2000; 1
Pollack MH (ref35) 2006; 59
Johnson MR (ref31) 1998; 43
Barnett SD (ref48) 2002; 16
Blanco C (ref10) 2003; 18
Londborg PD (ref28) 1998; 173
Sheikh JI (ref29) 2000; 15
Mitte K (ref8) 2005; 25
Dannon PN (ref62) 2002; 17
Cerra D (ref60) 2006; 163
Nemeroff CB (ref34) 2005; 66
Khaldi S (ref37) 2003; 23
Brawman-Mintzer O (ref54) 2005; 66
Bystrisky A (ref5) 2006; 11
Ballenger JC (ref1) 2000; 2
Keller MB (ref12) 2005; 66
Stein DJ (ref43) 2005
Pollack MH (ref53) 2006; 59
Stein DJ (ref4) 2004; 9
Baetz M (ref63) 1998; 43
Bandelow B (ref20) 2006; 67
Van Ameringen M (ref49) 2004; 65
Pollack MH (ref11) 2007
Kessler RC (ref2) 2005; 352
Robinson HM (ref30) 2006; 28
Boerner RJ (ref55) 1995; 22
Blier P (ref33) 2005; 66
Tiffon L (ref56) 1994; 55
Hetem LA (ref58) 1996; 16
Brawman-Mintzer O (ref18) 2005; 66
Ipser JC (ref7) 2006; 4
Tesar GE (ref36) 1986; 174
Baldwin DS (ref25) 2006; 189
Chao IL (ref64) 2004; 37
Stein MB (ref51) 2001; 158
Rickels K (ref24) 2003; 160
References_xml – volume: 67
  start-page: 381
  issn: 0160-6689
  issue: 3
  year: 2006
  ident: ref17
  article-title: An open-label trial of risperidone augmentation for refractory anxiety disorders
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v67n0307
  contributor:
    fullname: Simon NM
– volume: 66
  start-page: 1321
  issn: 0160-6689
  issue: 10
  year: 2005
  ident: ref54
  article-title: Adjunctive risperidone in generalized anxiety disorder: A double-blind, placebo- controlled study
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v66n1016
  contributor:
    fullname: Brawman-Mintzer O
– volume: 25
  start-page: 497
  issn: 0271-0749
  issue: 5
  year: 2005
  ident: ref16
  article-title: Open-label pilot study of ziprasidone for refractory generalized anxiety disorder
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/01.jcp.0000177853.15910.de
  contributor:
    fullname: Snyderman SH
– volume: 63
  start-page: 66
  issn: 0160-6689
  issue: 1
  year: 2002
  ident: ref27
  article-title: A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v63n0113
  contributor:
    fullname: Liebowitz MR
– volume: 51
  start-page: 8
  issn: 0003-990X
  issue: 1
  year: 1994
  ident: ref3
  article-title: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.1994.03950010008002
  contributor:
    fullname: Kessler RC
– volume: 67
  start-page: 1428
  issn: 0160-6689
  issue: 9
  year: 2006
  ident: ref20
  article-title: What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v67n0914
  contributor:
    fullname: Bandelow B
– volume: 157
  start-page: 659
  issn: 0002-953X
  issue: 4
  year: 2000
  ident: ref65
  article-title: Olanzapine and panic attacks
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.157.4.659-a
  contributor:
    fullname: Etxebeste M
– volume: 352
  start-page: 2515
  issn: 0028-4793
  issue: 24
  year: 2005
  ident: ref2
  article-title: Prevalence and treatment of mental disorders, 1990 to 2003
  publication-title: N Engl J Med
  doi: 10.1056/NEJMsa043266
  contributor:
    fullname: Kessler RC
– volume: 66
  start-page: 5
  year: 2005
  ident: ref12
  article-title: Issues in treatment-resistant depression
  publication-title: J Clin Psichiatry
  contributor:
    fullname: Keller MB
– volume: 23
  start-page: 100
  issn: 0271-0749
  issue: 1
  year: 2003
  ident: ref37
  article-title: Pelc I. Usefulness of olanzapine in refractory panic attacks
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/00004714-200302000-00015
  contributor:
    fullname: Khaldi S
– volume: 22
  start-page: 30
  issn: 0303-4259
  issue: 1
  year: 1995
  ident: ref55
  article-title: Treatment refractory panic disorder -success of a combined treatment with imipramine, moclobemide and behavior therapy
  publication-title: Psychiatr Prax
  contributor:
    fullname: Boerner RJ
– issn: 1091-4269
  year: 2007
  ident: ref11
  article-title: Novel treatment approaches for refractory anxiety disorders
  publication-title: Depress Anxiety
  contributor:
    fullname: Pollack MH
– volume: 14
  start-page: 239
  issn: 0268-1315
  issue: 4
  year: 1999
  ident: ref47
  article-title: Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders
  publication-title: Int Clin Psychopharmacol
  doi: 10.1097/00004850-199907000-00006
  contributor:
    fullname: Altamura AC
– volume: 16
  start-page: 77
  issn: 0271-0749
  issue: 1
  year: 1996
  ident: ref58
  article-title: Addition of d-fenfluramine to benzodiazepines produces a marked improvement in refractory panic disorder-a case report
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/00004714-199602000-00014
  contributor:
    fullname: Hetem LA
– volume: 62
  start-page: 656
  issn: 0160-6689
  issue: 8
  year: 2001
  ident: ref61
  article-title: Tiagabine improves panic and agoraphobia in panic disorder patients
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v62n0813d
  contributor:
    fullname: Zwanzger P
– volume: 2
  start-page: 35
  year: 2006
  ident: ref14
  article-title: Resistant social anxiety disorder response to Escitalopram
  publication-title: Clin Pract Epidemiol Ment Health
  doi: 10.1186/1745-0179-2-35
  contributor:
    fullname: Pallanti S
– volume: 18
  start-page: 169
  issn: 0268-1315
  issue: 3
  year: 2003
  ident: ref50
  article-title: Valproic acid for the treatment of social anxiety disorder
  publication-title: Int Clin Psychopharmacol
  contributor:
    fullname: Kinrys G
– volume: 66
  start-page: 13
  issn: 0160-6689
  year: 2005
  ident: ref34
  article-title: Use of atypical antipsychotic in refractory depression and anxiety
  publication-title: J Clin Psychiatry
  contributor:
    fullname: Nemeroff CB
– volume: 17
  start-page: 98
  issn: 1091-4269
  issue: 2
  year: 2003
  ident: ref22
  article-title: Predictors and outcomes in people told that they have panic attacks
  publication-title: Depress Anxiety
  doi: 10.1002/da.10086
  contributor:
    fullname: Katerndahl DA
– volume: 189
  start-page: 264
  issn: 0007-1250
  year: 2006
  ident: ref25
  article-title: Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study
  publication-title: Br J Psychiatry
  doi: 10.1192/bjp.bp.105.012799
  contributor:
    fullname: Baldwin DS
– volume: 43
  start-page: 306
  issn: 0006-3223
  issue: 4
  year: 1998
  ident: ref31
  article-title: Abnormal peripheral benzodiazepine receptor density associated with generalized social phobia
  publication-title: Biol Psychiatry
  doi: 10.1016/S0006-3223(97)00390-9
  contributor:
    fullname: Johnson MR
– volume: 57
  start-page: 313
  issue: 4
  year: 2003
  ident: ref42
  article-title: Phenelzine efficacy in refractory social anxiety disorder: a case series
  publication-title: Nord J Psychiatry
  doi: 10.1080/08039480310002110
  contributor:
    fullname: Aarre TF
– volume: 2
  start-page: 71
  issue: 3
  year: 2000
  ident: ref1
  article-title: Anxiety and depression: optimizing treatments
  publication-title: Prim Care Companion J Clin Psychiatry
  doi: 10.4088/PCC.v02n0301
  contributor:
    fullname: Ballenger JC
– volume: 20
  start-page: 9
  issn: 0268-1315
  issue: 1
  year: 2005
  ident: ref32
  article-title: Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients
  publication-title: Int Clin Psychopharmacol
  doi: 10.1097/00004850-200501000-00002
  contributor:
    fullname: Worthington JJ 3rd
– volume: 21
  start-page: 33
  issn: 1091-4269
  issue: 1
  year: 2005
  ident: ref39
  article-title: Potential effectiveness and safety of olanzapine in refractory panic disorder
  publication-title: Depress Anxiety
  doi: 10.1002/da.20050
  contributor:
    fullname: Hollifield M
– volume: 1
  start-page: 27
  issue: 1
  year: 2000
  ident: ref44
  article-title: A review of 19 double-blind placebo-controlled studies in social anxiety disorder (social phobia)
  publication-title: World J Biol Psychiatry
  doi: 10.3109/15622970009150563
  contributor:
    fullname: Versiani M
– volume: 18
  start-page: 29
  issn: 1091-4269
  issue: 1
  year: 2003
  ident: ref10
  article-title: Pharmacological treatment of social anxiety disorder: a meta-analysis
  publication-title: Depress Anxiety
  doi: 10.1002/da.10096
  contributor:
    fullname: Blanco C
– volume: 65
  start-page: 1674
  issn: 0160-6689
  issue: 12
  year: 2004
  ident: ref49
  article-title: An open-label trial of topiramate in the treatment of generalized social phobia
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v65n1213
  contributor:
    fullname: Van Ameringen M
– volume: 39
  start-page: 115
  issn: 0165-0327
  issue: 2
  year: 1996
  ident: ref45
  article-title: Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia
  publication-title: J Affect Disord
  doi: 10.1016/0165-0327(96)00030-4
  contributor:
    fullname: Van Ameringen M
– volume: 15
  start-page: 335
  issn: 0268-1315
  issue: 6
  year: 2000
  ident: ref29
  article-title: The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies
  publication-title: Int Clin Psychopharmacol
  doi: 10.1097/00004850-200015060-00004
  contributor:
    fullname: Sheikh JI
– volume: 27
  start-page: 207
  issn: 0271-0749
  issue: 2
  year: 2001
  ident: ref52
  article-title: An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/01.jcp.0000248620.34541.bc
  contributor:
    fullname: Menza MA
– volume: 163
  start-page: 548
  issn: 0002-953X
  issue: 3
  year: 2006
  ident: ref60
  article-title: Trimipramine for refractory panic attacks
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.163.3.548
  contributor:
    fullname: Cerra D
– volume: 158
  start-page: 1725
  issn: 0002-953X
  issue: 10
  year: 2001
  ident: ref51
  article-title: Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebocontrolled, crossover study
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.158.10.1725
  contributor:
    fullname: Stein MB
– volume: 173
  start-page: 54
  issn: 0007-1250
  year: 1998
  ident: ref28
  article-title: Sertraline in the treatment of panic disorder: A multi-site, double-blind, placebo-controlled, fixed-dose investigation
  publication-title: Br J Psychiatry
  doi: 10.1192/bjp.173.1.54
  contributor:
    fullname: Londborg PD
– volume: 26
  start-page: 45
  issn: 0271-0749
  issue: 1
  year: 2006
  ident: ref19
  article-title: Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/01.jcp.0000195108.01898.17
  contributor:
    fullname: Sepede G
– volume: 177
  start-page: 280
  issn: 0033-3158
  issue: 3
  year: 2005
  ident: ref26
  article-title: Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder
  publication-title: Psychopharmacology
  doi: 10.1007/s00213-004-1957-9
  contributor:
    fullname: Stein MB
– volume: 4
  start-page: CD005473
  year: 2006
  ident: ref7
  article-title: Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders
  publication-title: Cochrane Database Syst Rev
  contributor:
    fullname: Ipser JC
– volume: 20
  start-page: 556
  issn: 0271-0749
  issue: 5
  year: 2000
  ident: ref13
  article-title: Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/00004714-200010000-00011
  contributor:
    fullname: Hirschmann S
– volume: 31
  start-page: 335
  issn: 0706-7437
  issue: 4
  year: 1986
  ident: ref59
  article-title: Rapid response of a disorder to the addition of lithium carbonate: panic resistant to tricyclic antidepressants
  publication-title: Can J Psychiatry
  contributor:
    fullname: Cournoyer J
– volume: 160
  start-page: 749
  issn: 0002-953X
  issue: 4
  year: 2003
  ident: ref24
  article-title: Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.160.4.749
  contributor:
    fullname: Rickels K
– volume: 36
  start-page: 53
  issn: 0048-5764
  issue: 2
  year: 2002
  ident: ref40
  article-title: The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series
  publication-title: Psychopharmacol Bull
  contributor:
    fullname: Schwartz TL
– issue: 3
  year: 2005
  ident: ref43
  article-title: Pharmacotherapy for social anxiety disorder
  publication-title: The Cochrane Library
  contributor:
    fullname: Stein DJ
– volume: 24
  start-page: 617
  issue: 4
  year: 2001
  ident: ref6
  article-title: Epidemiology, patterns of comorbidity, and associated disabilities of social phobia
  publication-title: Psychiatr Clin N Am
  doi: 10.1016/S0193-953X(05)70254-9
  contributor:
    fullname: Wittchen HU
– volume: 17
  start-page: 329
  issue: 7
  year: 2002
  ident: ref62
  article-title: The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study
  publication-title: Hum Psychopharmacol
  doi: 10.1002/hup.421
  contributor:
    fullname: Dannon PN
– volume: 2
  start-page: 35
  year: 2006
  ident: ref38
  article-title: Resistant social anxiety disorder response to Escitalopram
  publication-title: Clin Pract Epidemol Ment Health
  doi: 10.1186/1745-0179-2-35
  contributor:
    fullname: Pallanti S
– volume: 68
  start-page: 335
  issn: 0160-6689
  issue: 2
  year: 2007
  ident: ref41
  article-title: Successful use of phenelzine in treatment-resistant panic disorder
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v68n0221e
  contributor:
    fullname: Buch S
– volume: 155
  start-page: 992
  issn: 0002-953X
  issue: 7
  year: 1998
  ident: ref15
  article-title: Gabapentin as a potential treatment for anxiety disorders
  publication-title: Am J Psychiatry
  doi: 10.1176/ajp.155.7.992
  contributor:
    fullname: Pollack MH
– volume: 25
  start-page: 141
  issn: 0271-0749
  issue: 2
  year: 2005
  ident: ref8
  article-title: A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/01.jcp.0000155821.74832.f9
  contributor:
    fullname: Mitte K
– volume: 88
  start-page: 27
  issn: 0165-0327
  issue: 1
  year: 2005
  ident: ref9
  article-title: A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia
  publication-title: J Affect Disord
  doi: 10.1016/j.jad.2005.05.003
  contributor:
    fullname: Mitte K
– volume: 7
  start-page: 655
  issue: 9
  year: 2002
  ident: ref46
  article-title: Citalopram for social anxiety disorder: an open-label pilot study in refractory and nonrefractory patients
  publication-title: CNS Spectr
  doi: 10.1017/S1092852900022148
  contributor:
    fullname: Simon NM
– volume: 66
  start-page: 1321
  issn: 0160-6689
  issue: 10
  year: 2005
  ident: ref18
  article-title: Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v66n1016
  contributor:
    fullname: Brawman-Mintzer O
– volume: 9
  start-page: 753
  issue: 10
  year: 2004
  ident: ref23
  article-title: Optimizing treatment in social phobia: a review of treatment resistance
  publication-title: CNS Spectr
  doi: 10.1017/S1092852900022392
  contributor:
    fullname: Van Ameringen M
– volume: 16
  start-page: 365
  issn: 0269-8811
  issue: 4
  year: 2002
  ident: ref48
  article-title: Efficacy of olanzapine in social anxiety disorder: a pilot study
  publication-title: J Psychopharmacol
  doi: 10.1177/026988110201600412
  contributor:
    fullname: Barnett SD
– volume: 37
  start-page: 239
  issn: 0031-7098
  issue: 5
  year: 2004
  ident: ref64
  article-title: Olanzapine augmentation in panic disorder: a case report
  publication-title: Pharmacopsychiatry
  doi: 10.1055/s-2004-832600
  contributor:
    fullname: Chao IL
– volume: 59
  start-page: 211
  issn: 0006-3223
  issue: 3
  year: 2006
  ident: ref53
  article-title: Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2005.07.005
  contributor:
    fullname: Pollack MH
– volume: 28
  start-page: 263
  issue: 4
  year: 2006
  ident: ref30
  article-title: Dopamine and social anxiety disorder
  publication-title: Rev Bras Psiquiatr
  doi: 10.1590/S1516-44462006000400003
  contributor:
    fullname: Robinson HM
– volume: 55
  start-page: 66
  issn: 0160-6689
  issue: 2
  year: 1994
  ident: ref56
  article-title: Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients
  publication-title: J Clin Psychiatry
  contributor:
    fullname: Tiffon L
– volume: 23
  start-page: 250
  issn: 0271-0749
  issue: 3
  year: 2003
  ident: ref21
  article-title: Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/01.jcp.0000084025.22282.84
  contributor:
    fullname: Pollack MH
– volume: 59
  start-page: 211
  issn: 0006-3223
  issue: 3
  year: 2006
  ident: ref35
  article-title: Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2005.07.005
  contributor:
    fullname: Pollack MH
– volume: 43
  start-page: 73
  issn: 0706-7437
  issue: 1
  year: 1998
  ident: ref63
  article-title: Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy
  publication-title: Can J Psychiatry
  doi: 10.1177/070674379804300109
  contributor:
    fullname: Baetz M
– volume: 11
  start-page: 805
  issn: 1359-4184
  issue: 9
  year: 2006
  ident: ref5
  article-title: Treatment-resistant anxiety disorders
  publication-title: Mol Psychiatry
  doi: 10.1038/sj.mp.4001852
  contributor:
    fullname: Bystrisky A
– volume: 174
  start-page: 477
  issn: 0022-3018
  issue: 8
  year: 1986
  ident: ref36
  article-title: Successful use of clonazepam in patients with treatment-resistant panic disorder
  publication-title: J Nerv Ment Dis
  doi: 10.1097/00005053-198608000-00006
  contributor:
    fullname: Tesar GE
– volume: 17
  start-page: 78
  issn: 1180-4882
  issue: 2
  year: 1992
  ident: ref57
  article-title: Sodium valproate and clonazepam for treatment-resistant panic disorder
  publication-title: J Psychiatry Neurosci
  contributor:
    fullname: Ontiveros A
– volume: 9
  start-page: 715
  issue: 10
  year: 2004
  ident: ref4
  article-title: Unresolved questions about treatment-resistant anxiety disorders
  publication-title: CNS Spectr
  doi: 10.1017/S1092852900022355
  contributor:
    fullname: Stein DJ
– volume: 66
  start-page: 30
  issn: 0160-6689
  year: 2005
  ident: ref33
  article-title: Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety
  publication-title: J Clin Psychiatry
  contributor:
    fullname: Blier P
SSID ssj0027387
Score 3.5518885
Snippet OBJETIVOS: Os transtornos de ansiedade são condições psiquiátricas prevalentes que determinam importante prejuízo funcional, piora na qualidade de vida do...
SourceID crossref
SourceType Aggregation Database
StartPage S55
Title Resistência ao tratamento nos transtornos de ansiedade: fobia social, transtorno de ansiedade generalizada e transtorno do pânico
Volume 29
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwELZKWVgQT_GWBzZTSNI8WrYWKAipDBQktspJXKkSSkrSDnTlnzDyN_qnGLmzUyflIShLlFqXs5v75HvGR8ghd4RrCM-quIFAB8V0K37P5RUPU7kGr1mhbJ3QvnGv7u3rB-ehVHovVC2Nhv5xMP72u5L_SBXGQK74lewcktVMYQDuQb5wBQnD9U8yvhUpSEnmuht4bAbjMfZ8GHIM-cUsilP8GWEBJN6HmCpIwebEs3arDdaLfXhGRc3xVee0M6TYZRkjV_0xDzkTM2QxG8jprQgQVTR0MecAhicDZzyFjaefcOQ5SPtPI9kaRGuDNjAfq73qkvvguD9y1oSRRD6RK0kstcckgwwkCPAfEpi8lePlcaSSSBjino7KYKBqWsXacp1mEqjCMx3p8HTNnN6cAUm2nYUsxTdj2Y6exVAUclPsjsqswibdUQcDZ_q-o_oZfFElTh1rLzt6AlyRPL4GzeBce04rBj4pVV3qiE4WsOpKRt0vjBbIouXVHadMFhvN82YrDxZUZXNHPX1WmwisTn5YU8GyKphIdytkOfNtaEMBdZWURLRGlrSKfV4nLwqxkzdEK-UxzdFKAaG0gFYaCqoheEolVqnC6lGBboaMFpFKxQxZTAeTV0TpBvFaF3dnV5Xp3-gO1Ikr3V9eYnWTlKM4EluEgvXqhLWeXTUC1w4Cw_dq9cDnvl3vhWZgmtvEmJf7zvyP7JKlHMB7pDxMRmIfjNehf5DJ-UAGfz4AosGbQA
link.rule.ids 315,786,790,870,27955,27956
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Resist%C3%AAncia+ao+tratamento+nos+transtornos+de+ansiedade%3A+fobia+social%2C+transtorno+de+ansiedade+generalizada+e+transtorno+do+p%C3%A2nico&rft.jtitle=Revista+brasileira+de+psiquiatria&rft.au=Menezes%2C+Gabriela+Bezerra+de&rft.au=Fontenelle%2C+Leonardo+F&rft.au=Mululo%2C+Sara&rft.au=Versiani%2C+M%C3%A1rcio&rft.date=2007-10-01&rft.issn=1516-4446&rft.eissn=1516-4446&rft.volume=29&rft.issue=suppl+2&rft.spage=S55&rft.epage=S60&rft_id=info:doi/10.1590%2FS1516-44462007000600004&rft.externalDBID=n%2Fa&rft.externalDocID=10_1590_S1516_44462007000600004
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1516-4446&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1516-4446&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1516-4446&client=summon